Xechem mit News - 500 Beiträge pro Seite

[LuckyLunatic]

Press Release Source: Xechem International, Inc.


Xechem Receives $473,181 SBIR Grant From NIH-NHLBI to Conduct Toxicity Studies of 5-HMF Compound
Wednesday October 4, 6:30 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that it has received a SBIR grant in the amount of $473,181 from the National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NHLBI) to carry out the toxicity studies on the five-membered heterocyclic anti-sickling compound known as 5-HMF. Researchers from both Virginia Commonwealth University (VCU) and Children's Hospital of Philadelphia (CHOP), University of Pennsylvania are expected to participate in the 5-HMF trials.

As previously reported, Xechem acquired the exclusive worldwide rights for 5-HMF in December 2005 under a license agreement with VCU and on May 26th, 2006, Xechem was successful in obtaining Orphan Drug designation from the US Food and Drug Administration (FDA) for the drug. Research led by Dr. Donald Abraham of VCU has shown 5-HMF to be "the best potential anti-sickling agent in 30 years of sickle cell research," performed by his group. 5-HMF not only is a natural product with very little, if any, toxicity, but it has a high affinity for sickle cell hemoglobin. It is also very active in genetically modified mice as shown by Dr. Toshio Asakura, and his colleagues at the NIH-NHLBI Sickle Cell Disease Reference Laboratory at CHOP.

According to Xechem's Chairman and CEO, Dr. Ramesh Pandey, "We are very pleased to have received this significant grant to fund the toxicity studies of 5-HMF, which has shown great promise as a new type of anti-sickling agent that interacts specifically with intracellular hemoglobin without interacting with other proteins in the body. The grant award will allow us to immediately move forward on the 5-HMF front as we continue with our ongoing efforts to expand our production capability for our first sickle cell drug (NICOSAN(TM)), which was launched in Nigeria on July 6th, 2006."

5-HMF is a single compound which, subject to further testing and trials, could be effective for intravenous and/or oral use in the fight against Sickle Cell Disease. Previously, the Company acquired the exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Federal Government of Nigeria, for the research, development, manufacture, marketing and distribution of NICOSAN(TM)/HEMOXIN(TM), an all Natural Herbal Drug (phyto-pharmaceutical) that was launched in Nigeria on July 6th, 2006.

About Sickle Cell Disease

Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval.

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.



Contact:
Xechem International, Inc.
Stephen Burg, 707-425-8855

[LuckyLunatic]

letzter 0,024 + 20%

[Roulett.Profi]

[Roulett.Profi]

Xechem erhält $ 473.181 SBIR gewähren von NIH-NHLBI, um Toxizitätsstudien über zu führen, 5-HMF zusammengesetzte
Mittwochsoktober4, 6:30 a.m. ET


neue BRUNSWICK, N.J. - (Geschäftsleitung) Xechem international, Inc. (OTC 2B: XKEM - Nachrichten) kündigte heute an, daß es eine SBIR Subvention im Betrag von $ 473.181 von den nationalen Instituten von Gesundheit, nationalen Herzen, Lunge und Blutinstitut (NIH-NHLBI) erhalten hat, um die Toxizitätsstudien auf der als 5-HMF gekannten five-membered heterocyclic anETBRUNSWICKN.J.XechemOTCXKEMSBIRNIHNHLBImemberedheterocyclicsicklingHMF Forscher von beider Virginia Commonwealthuniversität (VCU) und beiden Virginia Kindern\hat Krankenhaus von Philadelphia (Hieb), die Universität von Pennsylvanien wird an den 5-HMF Prüfungen teilzunehmen erwartet.


Als zuvor gemeldet, erwarb Xechem die exklusiven weltweiten Rechte für 5-HMF im Dezember 2005 unter einer Lizenzvereinbarung mit VCU von der US-Nahrungs- und Medikamentenverwaltung (FDA) und am 26. Mai 2006 war Xechem beim Erhalten der Waisenmedikamentenkennzeichnung erfolgreich von ihr für das Medikament. Von Dr. Donald Abraham von VCU geführte Forschung hat 5-HMF gezeigt zu sein "der am besten potentielle antisickling Agent in 30 Jahren der Sichelzellenforschung," geleistet von seiner Gruppe. 5-HMF ist nicht nur ein natürliches Produkt mit sehr wenig, wenn irgendwelche, Toxizität, aber es eine hohe Neigung zu Sichelzellenhämoglobin haben. Es ist auch in genetisch modifizierten Mäusen sehr aktiv, wie von Dr. Toshio Asakura und seinen Kollegen am NIH-NHLBI Sichelzellenkrankheitsreferenzlabor an Hieb gezeigt.

Entsprechend Xechem\hat Vorsitzender und Vorstandsvorsitzender, Dr. Ramesh Pandey "wir sind sehr erfreut, diese bedeutsame Subvention erhalten zu haben, um die Toxizitätsstudien über 5-HMF zu finanzieren, das großes Versprechen als eine neue Art des antisickling Agenten im Körper gezeigt hat, der ausdrücklich mit intracellular Hämoglobin interagiert, ohne mit anderen Eiweißen zu interagieren. Der Subventionspreis erlaubt uns bewegen sich sofort vorwärts auf der 5-HMF Vorderseite, da wir mit unseren andauernden Versuchen weitermachen, unsere Produktionsfähigkeit zu unserem ersten Sichelzellenmedikament (NICOSAN (TM)) auszudehnen, die in Nigeria am 6. Juli eingeführt wurde, 2006 . "

5-HMF ist eine einzelne Zusammensetzung, die abhängig von weiteren testend und Prüfungen gegen den intravenösen und/oder mündlichen Gebrauch im Kampf gegen Sichelzellenkrankheit wirksam sein konnte. >>> Previously, the Company acquired the exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Federal Government of Nigeria, for the research, development, manufacture, marketing and distribution of NICOSAN(TM)/HEMOXIN(TM), an all Natural Herbal Drug (phyto-pharmaceutical) that was launched in Nigeria on July 6th, 2006.

About Sickle Cell Disease

Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the Hämoglobinmolekül. Patienten mit der Krankheit produzieren oft steif, anormal geformte rote Blutzellen, die oft nicht reichlich durch die Blutgefäße fließen. Dies kann Holzschuhe in den Schiffen schaffen, welches wiederum kann vom Fluß von normalen Hämoglobin und Sauerstoff zu Teilen des Körpers schneiden und kann schwerwiegenden schmerzhaften Angriffen oder "Krisen" verursachen Schaden an verschiedenen Organen und verkürzten Lebensspannen. Leute mit SCD erleiden unvorhersehbare schmerzhafte Krisen oft mehrmals ein Jahr und reichen von einigen Stunden zu einer Woche oder mehr. In den US gibt es etwa 80.000 Patienten mit SCD. In Nigeria wird es geglaubt, daß diese Nummer etwa 4 Millionen mit einer geschätzten 10 - einen 12 Millionen Leidenden überall in dem afrikanischen Kontinent ist. Weltweit werden von mindestens 16 Millionen Personen geglaubt, daß sie mit SCD belastet werden.

[Roulett.Profi]

Wie darf man das verstehen

fast ne halbe Million Geschenkt

na dann Prost XKEM

[physik]

U.S. Ex-Im Bank has Approved Comprehensive Guarantee to Support $9.38 Million Loan from UPS Capital to Xechem Pharmaceuticals Nigeria
Wednesday October 18, 12:46 pm ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that the United States Export Import (Ex-Im) Bank, the official credit export agency of the United States, has approved a Comprehensive Credit Guarantee to support a $9.38 million loan from UPS Capital Business Credit to Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). Two Nigerian banks, Access Bank Plc. and Diamond Bank, Plc., are to provide the required Nigerian local bank guarantees in favor of Ex-Im Bank.

[stevie0902]

Ist nur noch eine Frage der Zeit bis diese Aktie durchbricht.
Hiermit kann man reich werden,man muss einfach nur einsteigen.

[physik]

XKEM Xechem Announces ``Notice of Allowance\'\' for a Patent Relating to a Method of Treating Sickle Cell Disease With 5-HMF Compound Licensed from VCU
Business Wire - October 23, 2006 7:00 AM (EDT)

NEW BRUNSWICK, N.J., Oct 23, 2006 (BUSINESS WIRE) -- Xechem International, Inc. (OTC BB: XKEM) announced today the United States Patent and Trademark Office has issued to Virginia Commonwealth University (VCU) a notice of patent allowance relating to a method of treating Sickle Cell Disease (SCD) with a unique 5-membered heterocyclic anti-sickling agent known as 5-HMF. A notice of allowance is a written notification that a patent application has cleared an internal review and is nearing issuance.

The exclusive, worldwide rights for the production, sales and marketing of 5-HMF for use in the battle against SCD belong to Xechem as part of a collaborative licensing agreement with VCU. In May 2006, Xechem was successful in obtaining Orphan Drug designation from the US Food and Drug Administration (FDA) for use of 5-HMF by patients afflicted with SCD.

Xechem also announced recently that it has received a SBIR grant in the amount of $473,181 from the National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NHLBI) to carry out the toxicity studies on 5-HMF.

5-HMF is a Pure Compound

Research led by Donald Abraham, Ph.D., professor of medicinal chemistry, VCU School of Pharmacy, has shown that 5-HMF, a pure compound with very little, if any, toxicity, has a high affinity for sickle cell hemoglobin and may be effective in the treatment of SCD. "Our findings suggest that this anti-sickling agent may lead to new drug treatments and may one day help those suffering with SCD. This molecule, 5-HMF, is the most promising molecule to treat sickle cell anemia to come from our research group in more than 30 years," Abraham said.

With the addition of 5-HMF, Xechem has now been able to expand its potent arsenal for treating Sickle Cell Disease beyond its Natural Herbal Drug, NICOSAN(TM), which was approved on July 3rd, 2006, by Nigeria\'s National Agency for Food and Drug Administration and Control (NAFDAC) and is currently being sold in Nigeria on a limited basis.

According to Xechem\'s Chairman and CEO, Dr. Ramesh C. Pandey, "With all of the excitement over the recent commercial launch in Nigeria of NICOSAN(TM), our all Natural Herbal Drug, there has been less attention focused on our other SCD product, 5-HMF, which also represents an extremely promising potential treatment for patients suffering with this terrible disease. As a pure compound, 5-HMF is the perfect complement to our herbal product and together with NICOSAN(TM) places us in a unique position of providing much needed efficacious treatment for this painful and debilitating condition. As the exclusive licensee for this product, we are very pleased to have the protections that a patent allowance affords to VCU and to us."

About Sickle Cell Disease

Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem\'s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval.

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.

SOURCE: Xechem International, Inc.

Xechem International, Inc.
Stephen Burg, Director, 707-425-8855

Copyright Business Wire 2006

[physik]

Xechem Announces Results of Annual Stockholder\'s Meeting
Tuesday October 24, 12:19 pm ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today the results of its Annual Stockholder Meeting, held earlier today at the company\'s offices in New Brunswick, New Jersey. Proxies representing a majority of the shares voted at the Annual Meeting were cast in favor of management and its policies and actions since the previous annual meeting, including the resolutions brought before the shareholders for a vote.
ADVERTISEMENT


Xechem\'s Chairman and CEO, Dr. Ramesh Pandey, updated shareholders on developments at the company, with emphasis on the strides made by its subsidiary, Xechem Pharmaceuticals Nigeria, Ltd., in commercializing NICOSAN(TM), its Natural Herbal Drug for the prophylactic management of Sickle Cell Disease (SCD). Included in Dr. Pandey\'s presentation were slides showing the progress made in the construction of the new state-of-the-art commercial scale production facility which will adhere to the cGMP standards at its premises in Abuja, Nigeria, presently slated for completion by mid to late 2007. Dr. Pandey also recounted for those in attendance the extraordinary transformation that has occurred since 2002, when Xechem was developing the drug with borrowed equipment in temporary lab space. Now, he said, Xechem has built a modern, cGLP standard pilot facility from the ground up that rivals any in Nigeria and is currently producing and selling limited quantities of the drug at the highest standards. According to Dr. Pandey, "When you consider how far we have come with the limited resources available to us, including receiving approval from Nigerian drug regulators in July of this year and our success in bringing the drug to market, I am very pleased with what we have accomplished in a relatively short period of time. To be sure, much work still lies ahead, but I am optimistic that our progress will continue to accelerate and I look forward to delivering rewards to our shareholders."

At the meeting, the current slate of directors, Dr. Pandey of Highland Park, New Jersey, Mr. Stephen Burg, of Fairfield, California and Dr. Adesoji Adelaja of Okemos, Michigan, were all re-elected by wide margins to the board of the company. Other resolutions passed by shareholders included the ratification of the company\'s selection of Moore Stephens P.C. as its auditors, the adoption of a Stock Option Award Plan authorizing the grant of options to purchase 150 million shares of the company\'s common stock, and an approval to an amendment to the company\'s certificate of incorporation to increase the number of authorized shares of common stock from 1,950,000,000 to 5,000,000,000.

Board Takes Action to Voluntarily Limit Company\'s Ability to Issue Shares Without Further Shareholder Action

Despite the approval by shareholders to increase the company\'s authorized share capital, Xechem\'s board of directors held a special meeting immediately following the conclusion of the Annual Meeting and passed a resolution restricting the ability of the company to issue more than 3.5 billion total shares without a further vote of the shareholders. According to Xechem\'s Chairman and CEO, Dr. Ramesh C. Pandey, "The resolution increasing the company\'s authorized share capital was never a reflection of any present intention by the Company to issue shares in the amount of the proposed increase, but rather was designed to give the company maximum flexibility to respond to ever-changing events and opportunities, and to provide a hedge against unforeseen and unanticipated circumstances. However, after listening to the concerns of our shareholders, the Board was persuaded to voluntarily limit the ability of the company to issue more than 3.5 billion shares without further authority from the shareholders. I believe that the Board\'s action in limiting the issuance of shares will allay shareholder concerns while still providing the company ample flexibility to respond to future circumstances."

http://biz.yahoo.com/bw/061024/20061024005922.html?.v=1

[wanderer173]

Posted by: bigdaddyc25
In reply to: None
Date:10/24/2006 11:26:12 PMPost #of 59405

Good job on the summaries boys. It was GREAT to meet those that were in attendance. We made contacts today that will be of most value in our continued DD.

Here is what I want to add:

1)Funding (Vitamin M - as Pandey called it)
They need about $20M to bring full scale product to market in Nigeria, and begin clinical trials and FDA app in US
- $9.3M already approved
- $4 - $5M expected from NEXIM
- ??? pre-purchase from the Nigerian govn\'t

The pre-purchase will be huge, and is close now. Company officals hinted at it all day, and kept telling us something was cooking, but could not yet give us the details. The Nigerian lady from the health ministry also hinted at it very strongly. I asked her clear cut, how could the Nigerian people afford the drug? She responded that the govn\'t was going to pay for it, and that she was told not to say anymore at this time.

2) Increase in AS
Basically dilution is just about done at XKEM. They restricted the 1.5B shares because they know they do not need them. They asked for 5B prior to completion of the UPS loan, and responded quickly to our concerns. They have left the remainder of the increase in tact, as a back-up for remainning funding. They also mentioned the need for employee incentives, and possible acquisitions. I do not belive O/S will go over 2.5B, and that they are making EVERY efforty possible to eliminate dilution.


3) Demand in Nigeria
The Nigerian Director of Schetsco, who was at the meeting, also surprised me, when he told us all that the Nigerian sufferers reported at approx 4M people, is grossly understated. He said that teh number is closer to 10M. He said that the only concern XKEM would have after the new factory is built, is how they are going to expand it. The Nigerian officials made it very clear that the drug works, and that the demand is huge right now.


4) US Market
Pandey stated that funding from above will also cover the beginning of US clinical trials. He also said that he expects US ap[proval in approx 2 years. The part that surprised me was that he said orphan status drugs sell for as high as $50,000 a year per patient in the US. This could be a $4B drug in the US alone. WOW and 7 years of 100% exclusivity.

5) Europe
The head of XKEM Europe, announced that XKEM is now able to sell NICOSAN in Europe. He announced this as great news to the whole group, and then Pandey and the gang danced around the follow up questions. I found this very interesting.

6) Institutional Investors

I was sitting beside TRYZ on one side, and teh HEAD of a Hedge Fund on the other side. I got the guys card, and will call him to discuss things further. His fund owns approx 13M shares. He told me that institutions are starting to notice XKEM. He also told me that there is alomost no short position on XKEM right now, and that the decrease in share price, was due to weak longs, and Chassman. His group is very bullish on XKEM. He also knows a lot of things we don\'t. For example, he told me that Chassmna does not vote at any of the meetings.

More will come as I remember. I was very impressed with the passion and energy form Pandey. He is smart and relentless. I have no doubt he will succeed.

later
BigD

[gerdass]

Antwort auf Beitrag Nr.: 24.396.065 von LuckyLunatic am 04.10.06 12:58:04

[physik]

Antwort auf Beitrag Nr.: 24.836.865 von wanderer173 am 25.10.06 08:50:00

interessant ist, daß BigD von den Fakten her ziemlich gut lag - nur glaubte er, daraus ein Timing ableiten zu können. Hoffentlich schreibt er weiter bei iHub. Er ist schon ziemlich nah am Unternehmen dran.

[physik]

news im anderen Thread.
Zusammengefaßt wurde folgendes veröffentlicht:
"1. significant increase in its pilot scale production of NICOSAN(TM) with the arrival of a long awaited and very important piece of equipment in Nigeria
2. allowing us to bring NICOSAN(TM) to as many as 30,000 patients per month within the next 90 days
3. the Company believes it could produce sufficient product to serve the needs of approximately 50,000 to 100,000 patients by year end. Our current price of the product could in such event generate approximately $1 million to $2 million per month
4. The contractors remain supportive and have continued to work despite delays in their scheduled payments based, in part, on their confidence in Xechem Nigeria's ability to close the various pending loan transactions.
5. Xechem Nigeria will be updating the company website (www.xechemnigeria.com) in the coming week. Please refer to the "gallery" section under the Xechem Nigeria website (http://xechemnigeria.com/gallery.htm) to view updated pictures of the construction progress. As Xechem Nigeria proceeds toward completion of the facility, stockholders will be kept informed.
6. Loan Status: US Ex-Im Bank: Xechem Pharmaceuticals Nigeria Ltd. ("XPNL") has now secured Final Commitment letters from two local Nigerian banks, Diamond Bank and Bank PHB, required by US Ex-Im Bank ("EXIM") when it approved a comprehensive credit guarantee to support UPS Capital's $9.38 million loan to XPNL in October 2006.
7. Loan Status: Nigerian Ex-Im Bank: Xechem Nigeria has been in long-standing negotiations with Nigerian Export-Import Bank ("NEXIM") to secure an additional loan of approximately $5 million (Five Million US Dollars) to fund the completion of the commercial scale production facility and to provide interim working capital
8. The reports from the patients using NICOSAN(TM) in Nigeria have been very positive and demand is continuing to increase on a world-wide basis"

[physik]

[physik]

xechem ist mit einem Satz in die Top-50 der meistdiskutierten Stocks hier bei W:0 gesprungen:

http://www.wallstreet-online.de/aktien/statistik/topboard-be…

[physik]

http://www.marketwire.com/mw/release_html_b1?release_id=2260…

"Early Indicator Stock on the Move for Tuesday, March 13, 2007: Scaling Up, Marketing, and Distributing for Growth!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- March 13, 2007 -- TheSUBWAY.com names the following stocks to its Stock Alert List: Xechem International, Inc. (OTCBB: XKEM), CytRx Corporation's (NASDAQ: CYTR), j2 Global Communications, Inc. (NASDAQ: JCOM), Marvell Tech (NASDAQ: MRVL).

Xechem International, Inc. (OTCBB: XKEM) just announced that its subsidiary Xechem Pharmaceuticals Nigeria Ltd. expects at least a significant increase in its pilot scale production of NICOSAN™ with the arrival of a long-awaited and very important piece of equipment in Nigeria. The device, a second spray dryer, will be joined by a third spray dryer currently in transit and scheduled to arrive in a few weeks. Installation of the second spray dryer just received is already underway; it should be operational within the next ten days.

Dr. Ramesh C. Pandey, the Chairman and CEO, stated, "With this acquisition, we can increase our pilot scale production dramatically, allowing us to bring NICOSAN™ to as many as 30,000 patients per month within the next 90 days, which would result in sales of approximately US$500,000 per month, assuming we are successful in scaling up and marketing and distributing the product. Upon our ability to raise sufficient funds to complete construction of our full scale facility on a timely basis, the Company believes it could produce sufficient product to serve the needs of approximately 50,000 to 100,000 patients by year end. Our current price of the product could in such event generate approximately $1 million to $2 million per month."

Other stocks highlighted include CytRx Corporation's (NASDAQ: CYTR): Stock Pick List, up 1% on 1 million shares, j2 Global Communications, Inc. (NASDAQ: JCOM): Stock Pick List, up 2% on 1 million shares, Marvell Tech (NASDAQ: MRVL): Stock Pick List, up 1% on 8 million shares.

"The real estate market continues to be the wild card in the broader economy, and even has stock market investors worried as well. Indeed, some markets saw price appreciation rates of as much as 50%, while the national average was better than 10%. But as home price trends tend to lag behind sales trends by about nine to 12 months, many are predicting home prices will be weakest in 2008 and perhaps even into 2009." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated thirty thousand dollars for XKEM. CRG was compensated one hundred twenty thousand dollars in past compensation for XKEM. CRG intends to sell its shares. CRG has sold approximately zero XKEM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.


CONTACT:
Capital Research Group
Charles Tamburello
954-217-8555
www.TheSUBWAY.com

SOURCE: TheSUBWAY.com"

[physik]

Die dramatischen News sind ja für nächste Woche angekündigt:
Ablöse des Alembic-loans?
Finanzierung der Baukredite?

[physik]

da ist der Baukredit:
Xechem’s Subsidiary Receives 2nd Phase Loan Approval from NEXIM Bank

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTCBB: XKEM) announced today that its subsidiary Xechem Pharmaceuticals Nigeria Ltd. received final approval from the Nigerian Export-Import (“NEXIM”) Bank on March 28, 2007 for an additional loan of N350 Million Naira (approximately $2.6 million US Dollars).

Dr. Ramesh C. Pandey, the Chairman and CEO, stated, “The proceeds of this loan, which we expect to receive in the coming days, will allow us to place the ongoing construction of our new full scale manufacturing facility on the highest priority level. We are going to work very closely with our contractors and our partners at the Sheda Science and Technology Complex (SHESTCO) property to facilitate as rapid a completion of the construction as possible.”

“We are very grateful to all who have worked so hard to make this happen,” Dr. Pandey continued, “and recognize the level of commitment the NEXIM Bank has made to help assure the people of Nigeria and ultimately the world that this important anti-sickling drug, discovered by a Nigerian research team at the National Institute for Research and Development (NIPRD), will be made available to all who need it.”

About NICOSAN™

NICOSAN™ is an anti-sickling drug originally developed as NIPRISAN by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell “crises” while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN™.

After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN™ is being marketed in Nigeria since July 6th, 2007 on a limited basis. NICOSAN™ has Orphan Drug Designation in the US and EU countries.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that: (i) Xechem Nigeria will be unable to consummate the closing of its currently proposed bank financings; (ii) there could be delays and/or cost overruns in connection with the build out of Xechem Nigeria’s pilot plant facility to a full scale commercial production facility; (iii) the Company and/or Xechem Nigeria could suffer significant dilution from the raising of additional capital until such point in time as they achieve cash flow break even status; (iv) doing business in Nigeria is subject to all of the risks of operation in a foreign country and associated political and regulatory risks; and (v) operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations.
Contacts

Xechem International, Inc.
Stephen Burg, 707-425-8855
Director

[physik]

vielleicht sollten die Neueinsteiger hier auch ein bisschen lesen worum es geht...

[physik]

Xechem die zweithäufigst diskutierte Aktie bei W:0

[physik]

eine schöne Zusammenfassung der jüngsten Ereignisse von gvsj im Hauptthread:
"ich will mal versuchen, das für fjell zu übernehmen, damit du noch kaufen kannst, bevor wir 100% höher stehen:

Bekannt ist, dass xkem ein ziemlich konkurenzloses Medikament für Sichelzellanämie-Kranke besitzt, das die Krankheit zwar nicht heilen kann, aber so lindert, dass die Betroffenen die teils extremen Krisen, die bei dieser Krankheit auftreten nicht mehr durchmachen müssen (wenn man es täglich nimmt). Wirksamkeit hat sich bisher als sehr hoch erwiesen, ohne Nebenwirkungen, da pflanzliches Medikament.

In kleinen Mengen wird auch schon produziert.

Für die richtige Produktion wird in Nigeria gerade eine Favbrik gebaut und das größte Problem war bisher die ungesicherte Finanzierung für diese Fabrik.

Im Sommer vergangenen Jahres hat man zwar die Zusage einer amerikanischen Bürgschaftsbank zur Absicherung des nötigen Kredits bekommen. Dazu gehören dann aber noch zwei nigerianische Banken, die den Kredit dann auch tatsächlich valutieren.

Man (vorallem BigD) hat den Abschluss dieser Finanzierung schon Anfang Feb. erwartet. Eine der beiden Banken ist dann aber kurzfristig abgesprungen und xkem musste vermelden, dass hierfür Ersatz gefunden werden muss (man hat auch schon den Namen der neuen Bank genannt), sich die Finanzierung also noch hinzieht.

Verschärft wurde das Problem dadurch, dass die Forderung eines Privatgläubigers über rund zwei Mio.(Alembic) zum Jahresende fällig wurde. Man hat diesen Kredit für horrende Konditionen zweimal um wenige Monate verlängert.

Das war der Tiefpunkt und man konnte wirklich nicht sagen, ob xkem so kurz vor dem Ziel draufgeht, bzw. von Alembic ans Messer geliefert wird.Ausserdem war das Vertrauen der anleger komplett zerstört. Die alternative zur Insolvenz wäre dann nur noch die massenhafte Dillution gewesen (auch nicht viel besser)

Seither hat xkem von einem privaten Investor etwas über 400k erhalten und am Mittwoch vergangene Woche verkündet, dass sie einen weiteren Kredit über ca. 2,5 mio (?) erhalten haben, der aber zusätzlich zu dem Hauptkredit über 9,6 mio. zu sehen ist.


Die Folge: Das Vertrauen, dass sie es doch in die Vollproduktion schaffen steigt zusehends. Zumindest die Sicherheit, dass weder kurzfristige insolvenz noch Dillution droht scheint mir zumindest jetzt gegeben.

Was jetzt noch erwartet wird, ist zum einen, dass der große Kredit über 9,6 mio bestätigt wird, der für die fertigstellung und maschinelle Aussattung zu verwenden ist. Anscheinend soll es auch noch einen weiteren Deal mit einem Privatinvestor geben, der über 5 mio. bereitstellen will (laut iHub schon unterzeichnet). Mit diesem Geld will man ein paar alte Probleme erschlagen, nämlich zum einen den Alembic-Kredit zurückzahlen und zum eine etwas unbequeme Heuschrecke (Chassman) die über ein paar hundert mio Aktien verfügt ruhig stellen.

Wenn das wirklich so kommt wie erwartet/erhofft, dann bricht für xkem ein völlig neues Zeitalter an. Dann können es nämlich nur noch unvorhersehbare äussere Einflusse sein, die den weg zum produzierenden Biotechunternehmen noch in diesem Jahr stoppen können. Jeder kann dann anhand der erwarteten Produktion - die Nachfrage ist schon da -selbst eine Rechnung erstellen was an Umsatz und Gewinn kurz- bis mittelfristig anfallen wird.

Die Range der durchaus nachvollziehbaren berechnungen, die hier aufgestellt wurden, reciht von 0,2 $ bis 2,0$.

So und jetzt viel Spass beim ausrechnen des Gewinns, wenn es nur zur Hälfte der pessimistischten Prognosen kommen sollte.
"

[Pekpek]

[Karlos81]

Antwort auf Beitrag Nr.: 28.652.862 von physik am 04.04.07 09:55:39

Vielen Dank für die Zusammenfassung physik !

[stevie0902]

Antwort auf Beitrag Nr.: 28.652.862 von physik am 04.04.07 09:55:39

Wer bei dem Kurs noch zögert ist selber schuld...

[KRASSA]

Antwort auf Beitrag Nr.: 28.652.862 von physik am 04.04.07 09:55:39

Sehr gut zusammen gefasst!!!

Bin seit July 06 investiert, glaubte u hoffte der Geschichte. Die Chancen waren nie besser als jetzt.!

[gvsj]

auch wenn der Kurs (noch) nicht so reagiert hat wie er eigentlich müsste, gehört diese news hier unbedingt rein:




Xechem Receives $7 Million From New Investors

NEW BRUNSWICK, NJ -- (MARKET WIRE) -- April 19, 2007 -- Xechem International, Inc. (OTCBB: XKEM) announced today that it has received just over $7 million in funding following the closing of a convertible debt financing transaction with a group of largely new investors in the Company. The initial closing of $4.9 million closed on April 4, 2007, with the balance of $2.1 million having closed on April 18, 2007. (For a detailed description of the specific terms of the transaction, see the Company\'s filing with the Securities and Exchange Commission under Form 8-K, which was filed on April 10, 2007, and the Company\'s 8-K/A, to be filed shortly). A portion of the proceeds of the financing ($1.1 million) was used to pay down approximately half of the remaining obligation to Alembic Ltd., with the balance to be used for payment of certain existing obligations, progress toward completion of the Nigerian production facility and general working capital purposes. This funding is in addition to the recently announced bank loan of approximately $2.7 million received by the Company\'s Nigerian subsidiary last week.

Dr. Ramesh Pandey, the Chairman and CEO of Xechem, stated, "This investment in Xechem\'s Future by a group of individuals and entities marks a new phase in Xechem\'s development and shows how the interest in our Company has now expanded to a larger pool of investors, including certain institutional investors that had previously been unwilling to fund our operations. Coming on the heels of the recently approved Nigerian bank loan of approximately $2.7 million, and with Ex-Im moving closer to approval, we have now accelerated the timetable for the completion of the commercial scale production facility in Nigeria for an opening during the fourth quarter of 2007, while also addressing working capital needs at the Company\'s corporate headquarters in New Brunswick, New Jersey."


Highlighted Links
The MacReport.Net

Xechem International Inc.




Dr. Pandey added, "I am also pleased that this transaction included lock-ups by a number of persons, including the holder of a significant convertible debt position, which greatly limit the ability to sell Xechem stock over the next several months as we progress toward full scale production and execution of our business plan."

About XECHEM

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem\'s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that: (i) Xechem Nigeria will be unable to consummate the closing of its proposed Ex-Im bank financing; (ii) there could be delays and/or cost overruns in connection with the build out of Xechem Nigeria\'s pilot plant facility to a full scale commercial production facility; (iii) the Company and/or Xechem Nigeria could suffer significant dilution from the raising of additional capital until such point in time as they achieve cash flow break even status; (iv) doing business in Nigeria is subject to all of the risks of operation in a foreign country and associated political and regulator risk; (v) the convertible debt financing will not solve all of Xechem\'s financial needs and has been issued at a price that was a discount to the then current market price for Xechem\'s common stock; (vi)the convertible debt laces ongoing obligations upon Xechem and the failure to meet those obligations could result in acceleration of the associate indebtedness; and (vii) operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations.







--------------------------------------------------------------------------------


For further information contact:
Stephen Burg
Director
Xechem International, Inc.
[phone]


SOURCE: Xechem International Inc.

[physik]

Xechem International Appoints New Board Member
MarketWire News Releases
Published: 05/18/07 05:30 AM CDT
Released By:
Xechem International, Inc.


Xechem International, Inc. (XKEM) announced today the recent addition of Dr. Robert Swift as the new member of the Board of Directors of Xechem International, Inc. Dr. Swift received his Ph.D. in Biochemistry from Michigan State University and his M.B.A. in Finance from Indiana University. He has 15 years of experience in molecular biology, cancer research, biopharmaceuticals, and medical devices, and over ten years of experience in drug research and pre-clinical development with Eli Lilly and Company. He worked as a biotechnology analyst and an investment banker for five years, and was the Director of Research in Life Sciences at C.E. Unterberg, Towbin. In 2001, he joined Origin Capital Management and was co-portfolio manager until 2004. Presently he serves as a healthcare consultant.

Dr. Ramesh C. Pandey, Chairman & CEO of the Xechem Companies, said, "We are very happy that Dr. Robert Swift has agreed to take an active role as a board member of our Company. His combined experience in healthcare financing and creating relationships for corporate finance transactions, including IPOs, Secondary Offerings and Private Placement in both early and late-stage companies, should be an asset to Xechem. I look forward to work with Dr. Swift and to capitalize on his skills and experience to help the Company's growth and success."

About Xechem

Xechem International is a development stage biopharmaceutical company with expertise in developing drugs for Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of proprietary technologies, including those used in the treatment of orphan diseases and phyto-pharmaceuticals (natural herbal drugs). Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

About NICOSAN™

NICOSAN™ is an anti-sickling drug originally researched by the scientists at the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria. In clinical studies conducted under NIPRD's auspices, the drug showed substantial reduction in the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN™.

After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN™ is being marketed in Nigeria since July 6th, 2007 on a limited basis. NICOSAN™ has Orphan Drug Designation in the US and EU countries.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that: (i) Xechem Nigeria will be unable to consummate the closing of its currently proposed bank financings; (ii) there could be delays and/or cost overruns in connection with the build out of Xechem Nigeria's pilot plant facility to a full scale commercial production facility; (iii) the Company and/or Xechem Nigeria could suffer significant dilution from the raising of additional capital until such point in time as they achieve cash flow break even status; (iv) doing business in Nigeria is subject to all of the risks of operation in a foreign country and associated political and regulatory risky and iv) operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations.

For further information contact:

H. Scott English
Director, Investor Relations
Xechem
[phone] ext. 37

[wilfonx]

Antwort auf Beitrag Nr.: 29.401.748 von physik am 21.05.07 12:23:03

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that the UPS Capital Business Credit and the United States Export Import (EX-IM) Bank has received all the required approvals in connection with a US $9.38 million EX-IM loan guarantee for Xechem Pharmaceuticals Nigeria, Ltd. (Xechem Nigeria). The UPS Bank has now approved the funding of the loan in accordance with the guidelines and requirements of the EX-IM Bank loan guarantee program.
ADVERTISEMENT


In October 2006, EX-IM Bank, the official credit export agency of the United States, had approved a Comprehensive Credit Guarantee to support the loan, subject to the condition that Xechem Nigeria obtains supporting guarantees from two suitable local banks. Diamond Bank Plc and Platinum Habib Bank Plc, both headquartered in Nigeria, have issued the required guarantees, paving the way for finalization and funding of the UPS loan. Personal guarantees were also provided to these banks by Dr. Ramesh C. Pandey, Chairman & CEO of Xechem International, Inc. and Xechem Pharmaceutical Nigeria Ltd., and two Nigerian Board members, Dr. Adesoji Adelaja (also a Xechem International Board Member) and Mr. Isaac Inyang. The loan is for a five year term, bearing interest at LIBOR plus 2.75% and requires semi annual reductions of principal at 10% per period, together with payment of accrued, unpaid interest.

Funds Earmarked for Equipment, Corporate Offices and Manufacturing Facility

The funds provided by UPS Capital under the EX-IM guaranteed loan will be used to purchase the U.S. manufactured pre-fabricated corporate offices, warehouse, plant equipment and machinery needed by Xechem Nigeria to establish a state-of-the-art facility in the outskirts of Abuja, Nigeria, which is slated for completion during the fourth quarter of this year. The UPS loan is in addition to a separate loan of N350 Million Naira (approximately $2.7 million US Dollars) made in April 2007 to Xechem Nigeria by the Nigerian Export-Import (NEXIM) Bank for construction of manufacturing facility related costs, which supplements the N150 Million Naira (approximately US $1,157,000) of funds previously advanced by NEXIM. The expanded facility, once completed, will enable Xechem Nigeria to produce commercial scale quantities of NICOSAN(TM), Xechem\'s breakthrough medicine for the prophylactic management of Sickle Cell Disease (SCD).

\"We are very pleased that all of the pieces to the approval and funding of this long awaited EX-IM guaranteed loan have finally come together,\" commented Dr. Ramesh C. Pandey, Chairman and CEO of Xechem Companies. \"We can now turn our full attention to realizing our dream of completing the state-of-the-art laboratories and a cGMP production facility in Nigeria which will help us in the production of commercial scale quantities of NICOSAN(TM) to meet the needs of the millions of people afflicted with this terrible disease.\"

Dr. Pandey added, \"We are very grateful to EX-IM Bank, UPS Business Credit, Diamond Bank and Bank PHB for their strong support for this important project and for helping us make the dream a reality. I am especially grateful to our consultants Financialbridge, Inc. and Mr. Isaac Inyang for their tireless efforts in seeing this through to a successful conclusion.\"

About NICOSAN(TM)

NICOSAN(TM) is an anti-sickling drug originally researched by the scientists at the National Institute for Pharmaceutical Research and Development (NIPRD) in Abuja, Nigeria. In clinical studies conducted under NIPRD\'s auspices, the drug showed substantial reduction in the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell \"crises\" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN(TM).

After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN(TM) is being marketed in Nigeria since July 6th, 2006 on a limited basis. NICOSAN(TM) has Orphan Drug Designation in the US and EU countries.

About Xechem

Xechem International is a development stage biopharmaceutical company with expertise in developing drugs for Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of proprietary technologies, including those used in the treatment of orphan diseases and phyto-pharmaceuticals (natural herbal drugs). Xechem\'s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended